Virtu Financial LLC Invests $219,000 in Cardlytics, Inc. (NASDAQ:CDLX)

Virtu Financial LLC bought a new position in Cardlytics, Inc. (NASDAQ:CDLX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 23,763 shares of the company’s stock, valued at approximately $219,000. Virtu Financial LLC owned approximately 0.06% of Cardlytics at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Cardlytics by 13.0% in the 3rd quarter. Vanguard Group Inc. now owns 2,011,705 shares of the company’s stock worth $33,193,000 after acquiring an additional 231,303 shares in the last quarter. Invesco Ltd. grew its position in shares of Cardlytics by 538.1% in the 3rd quarter. Invesco Ltd. now owns 803,241 shares of the company’s stock worth $13,253,000 after acquiring an additional 677,354 shares in the last quarter. General Equity Holdings LP grew its position in shares of Cardlytics by 31.0% in the 4th quarter. General Equity Holdings LP now owns 624,058 shares of the company’s stock worth $5,748,000 after acquiring an additional 147,843 shares in the last quarter. LPL Financial LLC grew its position in shares of Cardlytics by 27.5% in the 3rd quarter. LPL Financial LLC now owns 424,150 shares of the company’s stock worth $6,998,000 after acquiring an additional 91,400 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Cardlytics by 12.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 283,086 shares of the company’s stock worth $4,671,000 after acquiring an additional 32,228 shares in the last quarter. Institutional investors and hedge funds own 68.10% of the company’s stock.

Insider Buying and Selling at Cardlytics

In other news, insider Nicholas Hollmeyer Lynton sold 12,460 shares of the business’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $13.69, for a total value of $170,577.40. Following the sale, the insider now owns 71,355 shares of the company’s stock, valued at approximately $976,849.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Nicholas Hollmeyer Lynton sold 12,460 shares of the business’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $13.69, for a total value of $170,577.40. Following the sale, the insider now owns 71,355 shares of the company’s stock, valued at approximately $976,849.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Karim Saad Temsamani sold 43,129 shares of the business’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $8.65, for a total value of $373,065.85. Following the completion of the sale, the chief executive officer now directly owns 385,530 shares in the company, valued at approximately $3,334,834.50. The disclosure for this sale can be found here. Insiders have sold 79,435 shares of company stock valued at $828,269 in the last quarter. Corporate insiders own 4.40% of the company’s stock.

Cardlytics Stock Down 0.9 %

Shares of Cardlytics stock opened at $8.04 on Friday. The business’s fifty day moving average price is $10.41 and its two-hundred day moving average price is $9.56. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.13 and a quick ratio of 2.13. The company has a market capitalization of $392.19 million, a P/E ratio of -1.82 and a beta of 1.67. Cardlytics, Inc. has a 1-year low of $5.53 and a 1-year high of $20.52.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Wednesday, May 8th. The company reported ($0.35) earnings per share for the quarter. The business had revenue of $67.61 million for the quarter. Cardlytics had a negative net margin of 55.23% and a negative return on equity of 25.36%.

Wall Street Analyst Weigh In

CDLX has been the subject of several research reports. Northland Capmk upgraded Cardlytics to a “strong-buy” rating in a research report on Tuesday, June 18th. Bank of America reissued a “neutral” rating and issued a $11.00 price target on shares of Cardlytics in a report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $12.00 price target on shares of Cardlytics in a report on Tuesday, June 11th. Craig Hallum cut their price target on Cardlytics from $18.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, May 9th. Finally, Lake Street Capital raised their price target on Cardlytics from $13.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, March 15th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.67.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.